BioNTech Open to Preferred Partnership as Cancer Drugs Advance

BioNTech SE is flexible about its future structure as it prepares to bring a slew of cancer drugs to market, with its chief ...

BioNTech's Pivotal Year: Transitioning from Pandemic Success to Oncology Ambitions

A key enabler for BioNTech's ambitious plans is an exceptionally strong balance sheet, rare for a biotechnology company. As of the end of 2025, the Mainz-based firm reported liquid funds of ...
newscase

CureVac Stock Delisted Following BioNTech Acquisition Finalization

The independent journey of CureVac on public markets has concluded. The Nasdaq exchange has suspended trading of the ...

BioNTech Provides Strategic Business Update and Outlines 2026 Areas of Focus at 44th Annual J.P. Morgan Healthcare Conference

BioNTech with continued late-stage pipeline progress with candidates across immunomodulators, antibody-drug conjugates and mRNA immunotherapiesExpected 2026 oncology milestones include seven ...

Ugur Sahin

Ugur Sahin, M.D., Co-Founder and CEO of BioNTech, is a physician, immunologist and leader in the development of novel ...